Delving into the Latest Updates on Insulin enteric-coated(Tsinghua University) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesEndocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Tsinghua University

Active Organization

Tsinghua UniversityBeijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

To evaluate the change in glycated haemoglobin (HbA1c) from baseline after 24 weeks of insulin enteric-coated capsules combined with oral hypoglycemic drugs in patients with type 2 diabetes who were inadequately controlled with oral hypoglycemic drugs, compared with placebo combined with oral hypoglycemic drugs.

Start Date15 Apr 2020

Sponsor / Collaborator

Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd

[+1]

100 Clinical Results associated with Insulin enteric-coated(Tsinghua University)

Login to view more data

100 Translational Medicine associated with Insulin enteric-coated(Tsinghua University)

Login to view more data

100 Patents (Medical) associated with Insulin enteric-coated(Tsinghua University)

Login to view more data

100 Deals associated with Insulin enteric-coated(Tsinghua University)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Phase 3	CN	Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd	15 Apr 2020
Diabetes Mellitus, Type 1	Phase 3	CN	Tsinghua University	15 Apr 2020
Diabetes Mellitus, Type 2	Phase 3	CN	Tsinghua University	15 Apr 2020
Diabetes Mellitus, Type 2	Phase 3	CN	Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd	15 Apr 2020